Trials / Recruiting
RecruitingNCT06474533
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 199 (estimated)
- Sponsor
- Thomas Hope · Academic / Other
- Sex
- All
- Age
- 4 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Detailed description
PRIMARY OBJECTIVES: 1. To determine if FET Positron Emission Tomography (PET) scan can differentiate between benign treatment-related changes and recurrence in comparison to pathology in population 1 with recurrent metastatic disease and high-grade gliomas. 2. To determine if FET PET scan can differentiate between low-grade and high-grade gliomas in population 2. SECONDARY OBJECTIVES: 1. To determine if FET PET scan can differentiate between benign treatment- related changes and recurrence in comparison to pathology or imaging follow-up in population 1. 2. To determine if FET PET scan can differentiate between benign treatment- related changes and recurrence in comparison to pathology in population 1 with recurrent low-grade gliomas. EXPLORATORY OBJECTIVES: 1\. To assess relationships between serial FET PET scan and clinical outcome in population 1 with recurrent metastatic disease and gliomas. OUTLINE: Participants will receive a single PET scan lasting for about 40 minutes in an outpatient setting after an injection with FET. Adult participants may undergo up to two repeat FET PET scans. Adverse events will be recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluorethyltyrosine (18-F) | Given intravenously (IV) |
| PROCEDURE | Positron Emission Tomography (PET) | Undergo Imaging Procedure |
Timeline
- Start date
- 2024-06-21
- Primary completion
- 2028-08-31
- Completion
- 2028-08-31
- First posted
- 2024-06-25
- Last updated
- 2026-04-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06474533. Inclusion in this directory is not an endorsement.